Unknown

Dataset Information

0

Integrating Experimental and In Silico HTS in the Discovery of Inhibitors of Protein-Nucleic Acid Interactions.


ABSTRACT: Discovery of novel tool compounds and drug leads against a range of unorthodox protein targets has pushed both experimental screening methodologies as well as the field of structure-based design to the limit in recent years. Increasingly, it has been recognized that some of the most desirable targets for the development of small-molecule effectors are actually protein-protein and protein-nucleic acid interactions. There are numerous nontrivial challenges to pursuing small-molecule lead compounds directed toward PPIs and PNIs: relatively shallow cavities, large surface areas that are natively complexed to macromolecules, complex patterns of interstitial waters, a paucity of "hot spots," large conformational changes upon ligand binding, etc. Although there have been some notable successes targeting PPIs in the last decade, there has been distinctly less success in the realm of targeting PNIs. This chapter focuses on an approach, successfully applied by our group to address the challenge of gaining traction on the PPI target RAD52, which is a protein that binds both single-stranded and double-stranded DNA, and is an anticancer target for certain types of cancer. There are many approaches to tackling the difficult problems of finding effective small molecules that disrupt PPIs and PNIs, but the methods presented here offer a series of elegant solutions, which integrate experimental HTS, biophysical methods, docking, and molecular dynamics in a powerful way. Additionally, the structural knowledge gained from these studies provides a means for rationally understanding what features lead to ligand affinity in these fascinating and highly unorthodox pockets.

SUBMITTER: Li Q 

PROVIDER: S-EPMC6010167 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

altmetric image

Publications

Integrating Experimental and In Silico HTS in the Discovery of Inhibitors of Protein-Nucleic Acid Interactions.

Li Quinn Q   Folly da Silva Constantino Laura L   Spies M Ashley MA  

Methods in enzymology 20180228


Discovery of novel tool compounds and drug leads against a range of unorthodox protein targets has pushed both experimental screening methodologies as well as the field of structure-based design to the limit in recent years. Increasingly, it has been recognized that some of the most desirable targets for the development of small-molecule effectors are actually protein-protein and protein-nucleic acid interactions. There are numerous nontrivial challenges to pursuing small-molecule lead compounds  ...[more]

Similar Datasets

| S-EPMC8161098 | biostudies-literature
| S-EPMC6606840 | biostudies-literature
2024-10-25 | GSE279094 | GEO
| S-EPMC9420432 | biostudies-literature
| S-EPMC7497705 | biostudies-literature
| S-EPMC5733266 | biostudies-literature
| S-EPMC4744088 | biostudies-literature
| S-EPMC4271565 | biostudies-literature
| S-EPMC4384882 | biostudies-literature
| S-EPMC6188659 | biostudies-literature